Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma
Clinical Genitourinary Cancer · 2023-04 · 21 (2) · e35-e43
DOI: 10.1016/j.clgc.2022.09.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genitourinary Cancer, 2023-04. Verfasst von Floriane Izarn und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Centre Léon Bérard, Lyon, France; University Claude Bernard Lyon 1, Lyon, France. Electronic address: floriane.izarn@…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Metastatic non clear cell renal cell carcinoma (nccRCC) is an heterogenous group, usually excluded from phase 3 trials. We report real life data of prognosis and systemic management of those patients. METHODS: We retrospectively included 102 metastatic nccRCC patients (unspecified papillary, n = 10; type 1 and 2 papillary n = 10 and n = 32; translocation RCC, n = 9; chromophobe, n = 14; collecting duct, n = 14) treated between 2006 and 2020. Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated. RESULTS: Among patients who underwent pathological review, 40.8% presented a complete histological discordance. First line treatments were mainly tyrosine kinase inhibitor (60.8%), combination including immunotherapy (7.8%) or combination of chemotherapy (13.7%). Median ORR ranged from 0% in unspecified papillary RCC to 42.9% in type 1 papillary RCC. Median PFS ranged from 2.9 months in collecting duct carcinoma to 10.9 months in type 1 papillary RCC. Median OS ranged from 6.8 months in collecting duct carcinoma to 29.1 months in MiT family translocation RCC. Thirty (29.4%) patients were included in a treatment trial during their treatment course. CONCLUSION: Metastatic nccRCC patients have variable prognosis due to heterogeneity of histological subtypes. Their diagnosis and access to therapeutic innovation remain suboptimal. Dedicated prospective trials are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France; University Claude Bernard Lyon 1, Lyon, France. Electronic address: floriane.izarn@lyon.unicancer.fr.
- University Claude Bernard Lyon 1, Lyon, France; Department of Radiation Oncology, Centre Léon Bérard, Lyon, France; CREATIS, CNRS UMR 5220, Inserm U1206, INSA-Lyon, Université Jean Monnet Saint-Étienne, Université Claud…
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France; University Claude Bernard Lyon 1, Lyon, France.
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
Zitieren
APA
Izarn, F., Allignet, B., Gille, R., Boyle, H., Neidhardt, E. M., Négrier, S., & Fléchon, A. (2023). Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 21(2), e35-e43. https://doi.org/10.1016/j.clgc.2022.09.009
Vancouver
Izarn F, Allignet B, Gille R, Boyle H, Neidhardt EM, Négrier S, et al. Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer. 2023;21(2):e35-e43. doi:10.1016/j.clgc.2022.09.009
BibTeX
@article{Izarn2023,
author = {Izarn, Floriane and Allignet, Benoît and Gille, Romane and Boyle, Helen and Neidhardt, Eve-Marie and Négrier, Sylvie and Fléchon, Aude},
title = {Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma},
journal = {Clinical Genitourinary Cancer},
year = {2023},
volume = {21},
number = {2},
pages = {e35--e43},
doi = {10.1016/j.clgc.2022.09.009}
}
EUVIMED